GW Pharmaceuticals Plc

218.90+0.0900+0.04%Vol 336.59K1Y Perf 124.98%
Apr 16th, 2021 16:00 DELAYED
BID218.90 ASK218.98
Open218.74 Previous Close218.81
Pre-Market- After-Market218.90
 - -  - -%
Target Price
207.90 
Analyst Rating
Strong Buy 1.12
Potential %
-5.03 
Finscreener Ranking
★★★★     54.30
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     57.52
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     54.84
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap6.86B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
99.92 
Earnings Date
10th May 2021

Today's Price Range

218.35219.00

52W Range

87.07219.00

5 Year PE Ratio Range

-188.80-18.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.45%
1 Month
1.81%
3 Months
61.28%
6 Months
129.29%
1 Year
124.98%
3 Years
63.20%
5 Years
166.01%
10 Years
-

TickerPriceChg.Chg.%
GWPH218.900.09000.04
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
3.50
4.60
0.04
0.05
-48.10
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
92.90
-10.50
-8.10
-
-12.53
RevenueValueIndustryS&P 500US Markets
406.57M
12.89
275.19
88.84
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.68-0.93-36.76
Q03 2020-0.63-0.3642.86
Q02 2020-0.58-0.2851.72
Q01 2020-0.88-0.2472.73
Q04 2019-0.52-0.84-61.54
Q03 2019-0.87-0.4844.83
Q02 2019-1.74-0.7855.17
Q01 2019-2.97-2.3520.88
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.2221.43Positive
6/2021 QR-0.0357.14Positive
12/2021 FY0.605.26Positive
12/2022 FY4.98-4.05Negative
Next Report Date10th May 2021
Estimated EPS Next Report-0.02
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume336.59K
Shares Outstanding31.35M
Trades Count4.27K
Dollar Volume227.27M
Avg. Volume956.18K
Avg. Weekly Volume323.85K
Avg. Monthly Volume546.37K
Avg. Quarterly Volume1.04M

GW Pharmaceuticals Plc (NASDAQ: GWPH) stock closed at 218.9 per share at the end of the most recent trading day (a 0.04% change compared to the prior day closing price) with a volume of 336.60K shares and market capitalization of 6.86B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 1161 people. GW Pharmaceuticals Plc CEO is Justin David Gover.

The one-year performance of GW Pharmaceuticals Plc stock is 124.98%, while year-to-date (YTD) performance is 89.67%. GWPH stock has a five-year performance of 166.01%. Its 52-week range is between 87.07 and 219, which gives GWPH stock a 52-week price range ratio of 99.92%

GW Pharmaceuticals Plc currently has a PE ratio of -129.80, a price-to-book (PB) ratio of 9.28, a price-to-sale (PS) ratio of 16.90, a price to cashflow ratio of 19.00, a PEG ratio of 2.32, a ROA of -6.12%, a ROC of -7.39% and a ROE of -7.59%. The company’s profit margin is -12.53%, its EBITDA margin is -8.10%, and its revenue ttm is $406.57 Million , which makes it $12.89 revenue per share.

Of the last four earnings reports from GW Pharmaceuticals Plc, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.02 for the next earnings report. GW Pharmaceuticals Plc’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for GW Pharmaceuticals Plc is Strong Buy (1.12), with a target price of $207.9, which is -5.03% compared to the current price. The earnings rating for GW Pharmaceuticals Plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

GW Pharmaceuticals Plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

GW Pharmaceuticals Plc has a Buy technical analysis rating based on Technical Indicators (ADX : 40.12, ATR14 : 2.94, CCI20 : 123.91, Chaikin Money Flow : 0.29, MACD : 8.90, Money Flow Index : 50.30, ROC : 0.57, RSI : 78.08, STOCH (14,3) : 96.49, STOCH RSI : 1.00, UO : 75.95, Williams %R : -3.51), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of GW Pharmaceuticals Plc in the last 12-months were: Adam George (Option Excercise at a value of $1 526 182), Adam George (Sold 804 492 shares of value $8 962 251 ), Alicia Secor (Option Excercise at a value of $5), Cabot Brown (Option Excercise at a value of $5), Cabot Brown (Sold 4 020 shares of value $72 159 ), Catherine J. Mackey (Option Excercise at a value of $5), Christopher John Tovey (Option Excercise at a value of $159), Christopher John Tovey (Sold 122 028 shares of value $1 426 518 ), Darren S. Cline (Option Excercise at a value of $9), Douglas B. Snyder (Option Excercise at a value of $373), Douglas B. Snyder (Sold 83 508 shares of value $894 112 ), Geoffrey William Guy (Option Excercise at a value of $379), Geoffrey William Guy (Sold 1 747 152 shares of value $17 842 047 ), Justin David Gover (Option Excercise at a value of $851), Justin David Gover (Sold 180 000 shares of value $1 802 810 ), Scott Giacobello (Option Excercise at a value of $358), Volker Knappertz (Option Excercise at a value of $339), Volker Knappertz (Sold 60 000 shares of value $632 520 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (84.62 %)
12 (85.71 %)
11 (84.62 %)
Moderate Buy
2 (15.38 %)
2 (14.29 %)
2 (15.38 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.12
Strong Buy
1.11
Strong Buy
1.12

GW Pharmaceuticals Plc

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

CEO: Justin David Gover

Telephone: +44 1223266800

Address: Sovereign House, Chivers Way, Cambridge CB24 9BZ, , GB

Number of employees: 1 161

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

57%43%

Bearish Bullish

52%48%

News

Stocktwits